BRIM Biotechnology, Inc.
6885.TWO
Taipei Exchange21.00
TWD
-0.40
- -
BRIM Biotechnology, Inc.
6885.TWO
(Taipei Exchange)
Recent
price
21.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- BRIM Biotechnology, Inc. is a clinical-stage biotechnology company headquartered in Taipei, Taiwan, founded in 2013, specializing in the development of novel regenerative peptide therapies primarily targeting ophthalmology and degenerative joint diseases. The company’s core products and services are built around its proprietary Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP) technology platform, which is applied across multiple therapeutic areas including dry eye disease, severe corneal damage, neurotrophic keratitis, and osteoarthritis. Key product candidates include BRM421, a first-in-class topical ophthalmic solution in Phase 3 clinical trials for moderate-to-severe dry eye disease that promotes corneal repair; BRM423 for severe corneal damage in early clinical development; BRM424 for neurotrophic keratitis with orphan drug designation and ongoing Phase 2 trials; and BRM521 for alleviating tissue damage associated with osteoarthritis. BRIM also provides a technology platform enabling accelerated drug development and partner-ready clinical assets through its PDSP platform, which has anti-angiogenic, anti-tumorigenic, and neurotrophic functions facilitating wound healing and tissue regeneration. Recent major company developments include initiating Phase 3 enrollment for BRM421 in late 2024, expanding its ophthalmic product portfolio by licensing new glaucoma treatments BRM411 and BRM412, and strategic investment to acquire a 42% stake in Compass Bioinformatics to leverage AI-driven genomics for enhanced drug target identification and clinical trial patient stratification. These changes underscore BRIM’s strategic focus on accelerating peptide and small molecule therapeutic pipelines in ophthalmology and related disease areas with global clinical trials ongoing in the United States, Brazil, and Taiwan. The company operates with a virtual business model to efficiently progress early-stage drug candidates and maintains a growing pipeline addressing high unmet medical needs in the healthcare sector.